Premium
Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells
Author(s) -
Montgomery R. Bruce,
Bonham Michael,
Nelson Peter S.,
Grim Jonathan,
Makary Ekram,
Vessella Robert,
Stahl William L.
Publication year - 2005
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20246
Subject(s) - lncap , taxane , docetaxel , paclitaxel , cancer research , prostate cancer , tubulin , estrogen , biology , medicine , cancer , endocrinology , microtubule , breast cancer , microbiology and biotechnology
Background The present study was designed to determine if estrogens change microtubule polymerization and modulate cell cycle progression in vitro, related to modulation of tubulin expression and to determine if estrogens had antagonistic or synergistic effects with microtubule active agents. Methods cDNA array analysis of LNCaP cells treated with the estrogens, estradiol, estrone, diethylstilbestrol (DES), and 2‐methoxyestradiol (2‐ME) was carried out and the results confirmed by PCR and Western blotting. Microtubule arrays in cells treated with estrogens were assessed using indirect immunofluorescence. The effects of combining estrogens with taxane was assessed by MTT assay and flow cytometry for cell cycle kinetics. Human prostate cancer xenografts were treated with DES and docetaxel to assess the effects of combining estrogens and taxane in vivo. Results Treatment of LNCaP cells with DES and 2‐ME suppressed transcripts and protein for β‐tubulin isotype IVa. This effect on tubulin synthesis was not blocked by estrogen or androgen receptor modulators. Other estrogens had no effect on β‐tubulin expression. 2‐ME and DES decreased the density of microtubules. The administration of DES or 2‐ME with paclitaxel enhanced cytotoxicity and G 2 ‐M arrest in vitro. DES enhanced tumor suppression in a human prostate cancer xenograft model when combined with the taxane docetaxel. Conclusion The use of DES and 2‐ME enhances the effects of taxanes and may be a novel and important means of increasing therapeutic efficacy of cytotoxic chemotherapy against prostate carcinoma. © 2005 Wiley‐Liss, Inc.